Surrozen (SRZN)
(Delayed Data from NSDQ)
$8.57 USD
+0.68 (8.62%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $8.08 -0.49 (-5.72%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.57 USD
+0.68 (8.62%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $8.08 -0.49 (-5.72%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Zacks News
Catalent (CTLT) to Report Q3 Earnings: What's in the Cards? (Revised)
by Zacks Equity Research
Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.
Harrow Health (HROW) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Harrow Health's (HROW) first-quarter top line is likely to have been driven by its recent product launches.
Catalent (CTLT) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.
Here's Why Surrozen, Inc. (SRZN) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
Surrozen, Inc. (SRZN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Revvity (PKI) to Report Q1 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Revvity's (PKI) first-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for Life Sciences and Diagnostics franchise.
DaVita (DVA) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
High labor costs and inflationary pressures are likely to have weighed on DaVita's (DVA) first-quarter top line.
BD (BDX) Gears Up for Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have benefited Q2 sales.
What Awaits Lantheus Holdings (LNTH) This Earnings Season?
by Zacks Equity Research
Lantheus Holdings' (LNTH) first-quarter results are likely to reflect solid top-line results on the back of robust product adoption.
Zacks.com featured highlights include Lamb Weston, NeoGenomics, Surrozen, KE Holdings and Insperity
by Zacks Equity Research
Lamb Weston, NeoGenomics, Surrozen, KE Holdings and Insperity are part of the Zacks Screen of the Week article.
Here's Why You May Add Nektar (NKTR) Stock to Your Portfolio
by Zacks Equity Research
Here we discuss some reasons why investing in Nektar Therapeutics (NKTR) stock now is a good idea despite its several pipeline setbacks.
5 Top Stocks Likely to Come Up With Earnings Beat
by Sanghamitra Saha
These top-ranked stocks are likely to beat on the bottom line in their next releases. Tap Lamb Weston (LW), NeoGenomics (NEO), Surrozen (SRZN), KE Hodlings (BEKE) and Insperity (NSP).
Here's Why You Should Invest in Larimar (LRMR) Stock Now
by Zacks Equity Research
Here we discuss some reasons why investing in Larimar Therapeutics (LRMR) stock now is a good idea.
Here's Why You Can Add KalVista (KALV) Stock to Your Portfolio
by Zacks Equity Research
Here we discuss some reasons why investing in KalVista Pharmaceuticals (KALV) stock now is a good idea.
New Strong Buy Stocks for April 12th
by Zacks Equity Research
CELU, MGI, LRMR, EQRX and SRZN have been added to the Zacks Rank #1 (Strong Buy) List on April 12, 2023.
Surrozen, Inc. (SRZN) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Surrozen, Inc. (SRZN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.